Patients typically switch from carbamazepine (CBZ) or oxcarbazepine (OXC) to eslicarbazepine acetate (ESL) for at least 1 of 3 reasons: tolerability, simpler dosing, and/or efficacy. Since no evidence-based recommendations exist regarding the switching schedule, expert opinions may prove helpful for practitioners. In this supplement, expert epileptologists and clinical trialists share their experience about switching patients from CBZ or OXC to ESL.
Supplement
Click here or on the image below to read the supplement
Podcasts
Dr. Elinor Ben-Menachem discusses the case of a 28-year-old man with focal onset epilepsy who was switched from CBZ to ESL.
Dr. Toufic Fakhoury discusses the case of a 34-year-old female who became seizure-free after switching from OXC to ESL.
Dr. Mohamad Koubeissi discusses the case of a 22-year-old man with intractable epilepsy who was switched from OXC to ESL.
Dr. John Stern discusses the case of a 48-year-woman with tonic-clonic seizures who was switched from CBZ to ESL.
Dr. James Wheless discusses the case of an 8-year-old male who found relief having switched from OXC to ESL.
About the Faculty
Mohamad Koubeissi, MD
Professor of Neurology
Director, Epilepsy Center
George Washington University
Washington, DC
Elinor Ben-Menachem, MD
Professor
Institute of Neuroscience and Physiology
Department of Clinical Neurosciences
The Sahlgrenska Academy at the University of Gothenburg
Department of Neurology
Sahlgrenska University Hospital
Gothenburg, Sweden
Toufic Fakhoury, MD
Saint Joseph Health System
Lexington, KY
John Stern, MD
Professor, Department of Neurology
Director, Epilepsy Clinical Program
Director, Epilepsy Residency Training Program
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
James W. Wheless, MD
Professor and Chief, Department of Pediatric Neurology
Chair, Division of Pediatric Neurology
Director, Le Bonheur Comprehensive Epilepsy Program
Director, Le Bonheur Neuroscience Center
University of Tennessee Health Science Center
Memphis, TN